Deltex Medical sees pick up in surgical probe salesTuesday, March 26th, 2013
Strong sales of surgical probes to the NHS and elsewhere enabled oesophageal doppler monitoring (ODM) specialist Deltex Medical (LON:DEMG) to increase revenues by 9% in 2012.
Trading in the early part of the current year had also been satisfactory, Deltex said, with surgical probe sales ahead of 2012 in all direct markets, while distributor sales were also on target.
Deltex added that the growth this year to date in the UK has been achieved against a particularly strong period in the early part of last year.
There were also encouraging signs that a number of NHS hospitals are planning to increase significantly their use of Deltex’s products, it added.
Revenues overall for the year rose to £6.8mln from £6.3mln, helped by a 24% jump in surgical probe sales in the UK, which offset a decline in critical care probe and monitor revenues.
Losses for the year rose to £2.1mln from £1.5mln after higher one-off costs and marketing expenses.
Nigel Keen, Deltex’s chairman, said: “Deltex Medical has entered the next phase in its development as we move from the market creation phase into market development in the UK, with a number of other European countries set to follow.
“We have additionally put in place a process to accelerate significantly the creation of a mass market for our products in the USA.“